Board resignation marks further change for Akela
This article was originally published in Scrip
Canadian drug development company Akela Pharma has announced the resignation of its non-executive director, Raj Maheshwari. Mr Maheshwari has served on Akela's board since June 2008; there are no current plans to replace his position. His resignation follows a turbulent period for the company, which last month restructured its operations and reduced its headcount by a third in a bid to conserve cash.